 | • レポートコード：MRC2-11QY12368 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、134ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は感染症のグローバル市場について調査・分析したレポートです。種類別（抗菌薬、抗ウイルス薬、抗真菌薬、駆虫薬）市場規模、用途別（後天性免疫不全症候群、B型肝炎、C型肝炎、ヒトパピローマウイルス、院内感染メチシリン耐性黄色ブドウ球菌感染症、クラミジア・トラコマチス・淋菌）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別感染症の競争状況、市場シェア ・世界の感染症市場：種類別市場規模 2015年-2020年（抗菌薬、抗ウイルス薬、抗真菌薬、駆虫薬） ・世界の感染症市場：種類別市場規模予測 2021年-2026年（抗菌薬、抗ウイルス薬、抗真菌薬、駆虫薬） ・世界の感染症市場：用途別市場規模 2015年-2020年（後天性免疫不全症候群、B型肝炎、C型肝炎、ヒトパピローマウイルス、院内感染メチシリン耐性黄色ブドウ球菌感染症、クラミジア・トラコマチス・淋菌） ・世界の感染症市場：用途別市場規模予測 2021年-2026年（後天性免疫不全症候群、B型肝炎、C型肝炎、ヒトパピローマウイルス、院内感染メチシリン耐性黄色ブドウ球菌感染症、クラミジア・トラコマチス・淋菌） ・北米の感染症市場分析：米国、カナダ ・ヨーロッパの感染症市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの感染症市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の感染症市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの感染症市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：F. Hoffmann-La Roche、Gilead Sciences、GlaxoSmithKline、Johnson & Johnson、Merck、Pfizer、AbbVie、Astellas Pharma、AstraZeneca、Bayer、Bristol-Myers Squibb、Chimerix Pharmaceuticals、Cubist、Eli Lilly、Isis Pharmaceuticals、Mitsubishi Tanabe Pharma、Novartis、Sanofi、Vertex ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
When infection attacks the body, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic; including antitubercular), antiviral, antifungal and antiparasitic (including antiprotozoal and antihelminthic) agents.
Depending on the severity and the type of infection, the antibiotic may be given by mouth or by injection, or may be applied topically. Severe infections of the brain are usually treated with intravenous antibiotics. Sometimes, multiple antibiotics are used in case there is resistance to one antibiotic.
Market Analysis and Insights: Global Infectious Diseases Market
The global Infectious Diseases market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Infectious Diseases Scope and Market Size
Infectious Diseases market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Infectious Diseases market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
F. Hoffmann-La Roche
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck
Pfizer
AbbVie
Astellas Pharma
AstraZeneca
Bayer
Bristol-Myers Squibb
Chimerix Pharmaceuticals
Cubist
Eli Lilly
Isis Pharmaceuticals
Mitsubishi Tanabe Pharma
Novartis
Sanofi
Vertex
Market segment by Type, the product can be split into
Antibacterial drugs
Antiviral drugs
Antifungal drugs
Antiparasitic drugs
Market segment by Application, split into
Acquired Immune Deficiency Syndrome
Hepatitis B
Hepatitis C
Human Papillomavirus
Hospital acquired Methicillin-resistant Staphylococcus aureus infection
Chlamydia trachomatis and Neisseria Gonorrhea
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Infectious Diseases Revenue
1.4 Market by Type
1.4.1 Global Infectious Diseases Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Antibacterial drugs
1.4.3 Antiviral drugs
1.4.4 Antifungal drugs
1.4.5 Antiparasitic drugs
1.5 Market by Application
1.5.1 Global Infectious Diseases Market Share by Application: 2020 VS 2026
1.5.2 Acquired Immune Deficiency Syndrome
1.5.3 Hepatitis B
1.5.4 Hepatitis C
1.5.5 Human Papillomavirus
1.5.6 Hospital acquired Methicillin-resistant Staphylococcus aureus infection
1.5.7 Chlamydia trachomatis and Neisseria Gonorrhea
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Infectious Diseases Market Perspective (2015-2026)
2.2 Global Infectious Diseases Growth Trends by Regions
2.2.1 Infectious Diseases Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Infectious Diseases Historic Market Share by Regions (2015-2020)
2.2.3 Infectious Diseases Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Infectious Diseases Market Growth Strategy
2.3.6 Primary Interviews with Key Infectious Diseases Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Infectious Diseases Players by Market Size
3.1.1 Global Top Infectious Diseases Players by Revenue (2015-2020)
3.1.2 Global Infectious Diseases Revenue Market Share by Players (2015-2020)
3.1.3 Global Infectious Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Infectious Diseases Market Concentration Ratio
3.2.1 Global Infectious Diseases Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Infectious Diseases Revenue in 2019
3.3 Infectious Diseases Key Players Head office and Area Served
3.4 Key Players Infectious Diseases Product Solution and Service
3.5 Date of Enter into Infectious Diseases Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Infectious Diseases Historic Market Size by Type (2015-2020)
4.2 Global Infectious Diseases Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Infectious Diseases Market Size by Application (2015-2020)
5.2 Global Infectious Diseases Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Infectious Diseases Market Size (2015-2020)
6.2 Infectious Diseases Key Players in North America (2019-2020)
6.3 North America Infectious Diseases Market Size by Type (2015-2020)
6.4 North America Infectious Diseases Market Size by Application (2015-2020)
7 Europe
7.1 Europe Infectious Diseases Market Size (2015-2020)
7.2 Infectious Diseases Key Players in Europe (2019-2020)
7.3 Europe Infectious Diseases Market Size by Type (2015-2020)
7.4 Europe Infectious Diseases Market Size by Application (2015-2020)
8 China
8.1 China Infectious Diseases Market Size (2015-2020)
8.2 Infectious Diseases Key Players in China (2019-2020)
8.3 China Infectious Diseases Market Size by Type (2015-2020)
8.4 China Infectious Diseases Market Size by Application (2015-2020)
9 Japan
9.1 Japan Infectious Diseases Market Size (2015-2020)
9.2 Infectious Diseases Key Players in Japan (2019-2020)
9.3 Japan Infectious Diseases Market Size by Type (2015-2020)
9.4 Japan Infectious Diseases Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Infectious Diseases Market Size (2015-2020)
10.2 Infectious Diseases Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Infectious Diseases Market Size by Type (2015-2020)
10.4 Southeast Asia Infectious Diseases Market Size by Application (2015-2020)
11 India
11.1 India Infectious Diseases Market Size (2015-2020)
11.2 Infectious Diseases Key Players in India (2019-2020)
11.3 India Infectious Diseases Market Size by Type (2015-2020)
11.4 India Infectious Diseases Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Infectious Diseases Market Size (2015-2020)
12.2 Infectious Diseases Key Players in Central & South America (2019-2020)
12.3 Central & South America Infectious Diseases Market Size by Type (2015-2020)
12.4 Central & South America Infectious Diseases Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 F. Hoffmann-La Roche
13.1.1 F. Hoffmann-La Roche Company Details
13.1.2 F. Hoffmann-La Roche Business Overview
13.1.3 F. Hoffmann-La Roche Infectious Diseases Introduction
13.1.4 F. Hoffmann-La Roche Revenue in Infectious Diseases Business (2015-2020))
13.1.5 F. Hoffmann-La Roche Recent Development
13.2 Gilead Sciences
13.2.1 Gilead Sciences Company Details
13.2.2 Gilead Sciences Business Overview
13.2.3 Gilead Sciences Infectious Diseases Introduction
13.2.4 Gilead Sciences Revenue in Infectious Diseases Business (2015-2020)
13.2.5 Gilead Sciences Recent Development
13.3 GlaxoSmithKline
13.3.1 GlaxoSmithKline Company Details
13.3.2 GlaxoSmithKline Business Overview
13.3.3 GlaxoSmithKline Infectious Diseases Introduction
13.3.4 GlaxoSmithKline Revenue in Infectious Diseases Business (2015-2020)
13.3.5 GlaxoSmithKline Recent Development
13.4 Johnson & Johnson
13.4.1 Johnson & Johnson Company Details
13.4.2 Johnson & Johnson Business Overview
13.4.3 Johnson & Johnson Infectious Diseases Introduction
13.4.4 Johnson & Johnson Revenue in Infectious Diseases Business (2015-2020)
13.4.5 Johnson & Johnson Recent Development
13.5 Merck
13.5.1 Merck Company Details
13.5.2 Merck Business Overview
13.5.3 Merck Infectious Diseases Introduction
13.5.4 Merck Revenue in Infectious Diseases Business (2015-2020)
13.5.5 Merck Recent Development
13.6 Pfizer
13.6.1 Pfizer Company Details
13.6.2 Pfizer Business Overview
13.6.3 Pfizer Infectious Diseases Introduction
13.6.4 Pfizer Revenue in Infectious Diseases Business (2015-2020)
13.6.5 Pfizer Recent Development
13.7 AbbVie
13.7.1 AbbVie Company Details
13.7.2 AbbVie Business Overview
13.7.3 AbbVie Infectious Diseases Introduction
13.7.4 AbbVie Revenue in Infectious Diseases Business (2015-2020)
13.7.5 AbbVie Recent Development
13.8 Astellas Pharma
13.8.1 Astellas Pharma Company Details
13.8.2 Astellas Pharma Business Overview
13.8.3 Astellas Pharma Infectious Diseases Introduction
13.8.4 Astellas Pharma Revenue in Infectious Diseases Business (2015-2020)
13.8.5 Astellas Pharma Recent Development
13.9 AstraZeneca
13.9.1 AstraZeneca Company Details
13.9.2 AstraZeneca Business Overview
13.9.3 AstraZeneca Infectious Diseases Introduction
13.9.4 AstraZeneca Revenue in Infectious Diseases Business (2015-2020)
13.9.5 AstraZeneca Recent Development
13.10 Bayer
13.10.1 Bayer Company Details
13.10.2 Bayer Business Overview
13.10.3 Bayer Infectious Diseases Introduction
13.10.4 Bayer Revenue in Infectious Diseases Business (2015-2020)
13.10.5 Bayer Recent Development
13.11 Bristol-Myers Squibb
10.11.1 Bristol-Myers Squibb Company Details
10.11.2 Bristol-Myers Squibb Business Overview
10.11.3 Bristol-Myers Squibb Infectious Diseases Introduction
10.11.4 Bristol-Myers Squibb Revenue in Infectious Diseases Business (2015-2020)
10.11.5 Bristol-Myers Squibb Recent Development
13.12 Chimerix Pharmaceuticals
10.12.1 Chimerix Pharmaceuticals Company Details
10.12.2 Chimerix Pharmaceuticals Business Overview
10.12.3 Chimerix Pharmaceuticals Infectious Diseases Introduction
10.12.4 Chimerix Pharmaceuticals Revenue in Infectious Diseases Business (2015-2020)
10.12.5 Chimerix Pharmaceuticals Recent Development
13.13 Cubist
10.13.1 Cubist Company Details
10.13.2 Cubist Business Overview
10.13.3 Cubist Infectious Diseases Introduction
10.13.4 Cubist Revenue in Infectious Diseases Business (2015-2020)
10.13.5 Cubist Recent Development
13.14 Eli Lilly
10.14.1 Eli Lilly Company Details
10.14.2 Eli Lilly Business Overview
10.14.3 Eli Lilly Infectious Diseases Introduction
10.14.4 Eli Lilly Revenue in Infectious Diseases Business (2015-2020)
10.14.5 Eli Lilly Recent Development
13.15 Isis Pharmaceuticals
10.15.1 Isis Pharmaceuticals Company Details
10.15.2 Isis Pharmaceuticals Business Overview
10.15.3 Isis Pharmaceuticals Infectious Diseases Introduction
10.15.4 Isis Pharmaceuticals Revenue in Infectious Diseases Business (2015-2020)
10.15.5 Isis Pharmaceuticals Recent Development
13.16 Mitsubishi Tanabe Pharma
10.16.1 Mitsubishi Tanabe Pharma Company Details
10.16.2 Mitsubishi Tanabe Pharma Business Overview
10.16.3 Mitsubishi Tanabe Pharma Infectious Diseases Introduction
10.16.4 Mitsubishi Tanabe Pharma Revenue in Infectious Diseases Business (2015-2020)
10.16.5 Mitsubishi Tanabe Pharma Recent Development
13.17 Novartis
10.17.1 Novartis Company Details
10.17.2 Novartis Business Overview
10.17.3 Novartis Infectious Diseases Introduction
10.17.4 Novartis Revenue in Infectious Diseases Business (2015-2020)
10.17.5 Novartis Recent Development
13.18 Sanofi
10.18.1 Sanofi Company Details
10.18.2 Sanofi Business Overview
10.18.3 Sanofi Infectious Diseases Introduction
10.18.4 Sanofi Revenue in Infectious Diseases Business (2015-2020)
10.18.5 Sanofi Recent Development
13.19 Vertex
10.19.1 Vertex Company Details
10.19.2 Vertex Business Overview
10.19.3 Vertex Infectious Diseases Introduction
10.19.4 Vertex Revenue in Infectious Diseases Business (2015-2020)
10.19.5 Vertex Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Infectious Diseases Key Market Segments
Table 2. Key Players Covered: Ranking by Infectious Diseases Revenue
Table 3. Ranking of Global Top Infectious Diseases Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Infectious Diseases Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Antibacterial drugs
Table 6. Key Players of Antiviral drugs
Table 7. Key Players of Antifungal drugs
Table 8. Key Players of Antiparasitic drugs
Table 9. Global Infectious Diseases Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Infectious Diseases Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Infectious Diseases Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Infectious Diseases Market Share by Regions (2015-2020)
Table 13. Global Infectious Diseases Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Infectious Diseases Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Infectious Diseases Market Growth Strategy
Table 19. Main Points Interviewed from Key Infectious Diseases Players
Table 20. Global Infectious Diseases Revenue by Players (2015-2020) (Million US$)
Table 21. Global Infectious Diseases Market Share by Players (2015-2020)
Table 22. Global Top Infectious Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Infectious Diseases as of 2019)
Table 23. Global Infectious Diseases by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Infectious Diseases Product Solution and Service
Table 26. Date of Enter into Infectious Diseases Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Infectious Diseases Market Size by Type (2015-2020) (Million US$)
Table 29. Global Infectious Diseases Market Size Share by Type (2015-2020)
Table 30. Global Infectious Diseases Revenue Market Share by Type (2021-2026)
Table 31. Global Infectious Diseases Market Size Share by Application (2015-2020)
Table 32. Global Infectious Diseases Market Size by Application (2015-2020) (Million US$)
Table 33. Global Infectious Diseases Market Size Share by Application (2021-2026)
Table 34. North America Key Players Infectious Diseases Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Infectious Diseases Market Share (2019-2020)
Table 36. North America Infectious Diseases Market Size by Type (2015-2020) (Million US$)
Table 37. North America Infectious Diseases Market Share by Type (2015-2020)
Table 38. North America Infectious Diseases Market Size by Application (2015-2020) (Million US$)
Table 39. North America Infectious Diseases Market Share by Application (2015-2020)
Table 40. Europe Key Players Infectious Diseases Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Infectious Diseases Market Share (2019-2020)
Table 42. Europe Infectious Diseases Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Infectious Diseases Market Share by Type (2015-2020)
Table 44. Europe Infectious Diseases Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Infectious Diseases Market Share by Application (2015-2020)
Table 46. China Key Players Infectious Diseases Revenue (2019-2020) (Million US$)
Table 47. China Key Players Infectious Diseases Market Share (2019-2020)
Table 48. China Infectious Diseases Market Size by Type (2015-2020) (Million US$)
Table 49. China Infectious Diseases Market Share by Type (2015-2020)
Table 50. China Infectious Diseases Market Size by Application (2015-2020) (Million US$)
Table 51. China Infectious Diseases Market Share by Application (2015-2020)
Table 52. Japan Key Players Infectious Diseases Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Infectious Diseases Market Share (2019-2020)
Table 54. Japan Infectious Diseases Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Infectious Diseases Market Share by Type (2015-2020)
Table 56. Japan Infectious Diseases Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Infectious Diseases Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Infectious Diseases Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Infectious Diseases Market Share (2019-2020)
Table 60. Southeast Asia Infectious Diseases Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Infectious Diseases Market Share by Type (2015-2020)
Table 62. Southeast Asia Infectious Diseases Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Infectious Diseases Market Share by Application (2015-2020)
Table 64. India Key Players Infectious Diseases Revenue (2019-2020) (Million US$)
Table 65. India Key Players Infectious Diseases Market Share (2019-2020)
Table 66. India Infectious Diseases Market Size by Type (2015-2020) (Million US$)
Table 67. India Infectious Diseases Market Share by Type (2015-2020)
Table 68. India Infectious Diseases Market Size by Application (2015-2020) (Million US$)
Table 69. India Infectious Diseases Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Infectious Diseases Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Infectious Diseases Market Share (2019-2020)
Table 72. Central & South America Infectious Diseases Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Infectious Diseases Market Share by Type (2015-2020)
Table 74. Central & South America Infectious Diseases Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Infectious Diseases Market Share by Application (2015-2020)
Table 76. F. Hoffmann-La Roche Company Details
Table 77. F. Hoffmann-La Roche Business Overview
Table 78. F. Hoffmann-La Roche Product
Table 79. F. Hoffmann-La Roche Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 80. F. Hoffmann-La Roche Recent Development
Table 81. Gilead Sciences Company Details
Table 82. Gilead Sciences Business Overview
Table 83. Gilead Sciences Product
Table 84. Gilead Sciences Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 85. Gilead Sciences Recent Development
Table 86. GlaxoSmithKline Company Details
Table 87. GlaxoSmithKline Business Overview
Table 88. GlaxoSmithKline Product
Table 89. GlaxoSmithKline Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 90. GlaxoSmithKline Recent Development
Table 91. Johnson & Johnson Company Details
Table 92. Johnson & Johnson Business Overview
Table 93. Johnson & Johnson Product
Table 94. Johnson & Johnson Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 95. Johnson & Johnson Recent Development
Table 96. Merck Company Details
Table 97. Merck Business Overview
Table 98. Merck Product
Table 99. Merck Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 100. Merck Recent Development
Table 101. Pfizer Company Details
Table 102. Pfizer Business Overview
Table 103. Pfizer Product
Table 104. Pfizer Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 105. Pfizer Recent Development
Table 106. AbbVie Company Details
Table 107. AbbVie Business Overview
Table 108. AbbVie Product
Table 109. AbbVie Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 110. AbbVie Recent Development
Table 111. Astellas Pharma Business Overview
Table 112. Astellas Pharma Product
Table 113. Astellas Pharma Company Details
Table 114. Astellas Pharma Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 115. Astellas Pharma Recent Development
Table 116. AstraZeneca Company Details
Table 117. AstraZeneca Business Overview
Table 118. AstraZeneca Product
Table 119. AstraZeneca Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 120. AstraZeneca Recent Development
Table 121. Bayer Company Details
Table 122. Bayer Business Overview
Table 123. Bayer Product
Table 124. Bayer Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 125. Bayer Recent Development
Table 126. Bristol-Myers Squibb Company Details
Table 127. Bristol-Myers Squibb Business Overview
Table 128. Bristol-Myers Squibb Product
Table 129. Bristol-Myers Squibb Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 130. Bristol-Myers Squibb Recent Development
Table 131. Chimerix Pharmaceuticals Company Details
Table 132. Chimerix Pharmaceuticals Business Overview
Table 133. Chimerix Pharmaceuticals Product
Table 134. Chimerix Pharmaceuticals Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 135. Chimerix Pharmaceuticals Recent Development
Table 136. Cubist Company Details
Table 137. Cubist Business Overview
Table 138. Cubist Product
Table 139. Cubist Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 140. Cubist Recent Development
Table 141. Eli Lilly Company Details
Table 142. Eli Lilly Business Overview
Table 143. Eli Lilly Product
Table 144. Eli Lilly Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 145. Eli Lilly Recent Development
Table 146. Isis Pharmaceuticals Company Details
Table 147. Isis Pharmaceuticals Business Overview
Table 148. Isis Pharmaceuticals Product
Table 149. Isis Pharmaceuticals Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 150. Isis Pharmaceuticals Recent Development
Table 151. Mitsubishi Tanabe Pharma Company Details
Table 152. Mitsubishi Tanabe Pharma Business Overview
Table 153. Mitsubishi Tanabe Pharma Product
Table 154. Mitsubishi Tanabe Pharma Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 155. Mitsubishi Tanabe Pharma Recent Development
Table 156. Novartis Company Details
Table 157. Novartis Business Overview
Table 158. Novartis Product
Table 159. Novartis Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 160. Novartis Recent Development
Table 161. Sanofi Company Details
Table 162. Sanofi Business Overview
Table 163. Sanofi Product
Table 164. Sanofi Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 165. Sanofi Recent Development
Table 166. Vertex Company Details
Table 167. Vertex Business Overview
Table 168. Vertex Product
Table 169. Vertex Revenue in Infectious Diseases Business (2015-2020) (Million US$)
Table 170. Vertex Recent Development
Table 171. Research Programs/Design for This Report
Table 172. Key Data Information from Secondary Sources
Table 173. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Infectious Diseases Market Share by Type: 2020 VS 2026
Figure 2. Antibacterial drugs Features
Figure 3. Antiviral drugs Features
Figure 4. Antifungal drugs Features
Figure 5. Antiparasitic drugs Features
Figure 6. Global Infectious Diseases Market Share by Application: 2020 VS 2026
Figure 7. Acquired Immune Deficiency Syndrome Case Studies
Figure 8. Hepatitis B Case Studies
Figure 9. Hepatitis C Case Studies
Figure 10. Human Papillomavirus Case Studies
Figure 11. Hospital acquired Methicillin-resistant Staphylococcus aureus infection Case Studies
Figure 12. Chlamydia trachomatis and Neisseria Gonorrhea Case Studies
Figure 13. Infectious Diseases Report Years Considered
Figure 14. Global Infectious Diseases Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Infectious Diseases Market Share by Regions: 2020 VS 2026
Figure 16. Global Infectious Diseases Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Infectious Diseases Market Share by Players in 2019
Figure 19. Global Top Infectious Diseases Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Infectious Diseases as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Infectious Diseases Revenue in 2019
Figure 21. North America Infectious Diseases Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Infectious Diseases Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Infectious Diseases Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Infectious Diseases Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Infectious Diseases Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Infectious Diseases Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Infectious Diseases Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Bottom-up and Top-down Approaches for This Report
Figure 29. Data Triangulation
Figure 30. Key Executives Interviewed
POC感染性疾患の世界市場（～2026年） POC diagnosis for infectious diseases refers to diagnostic tests performed near the site of patient care. Advances in POC technology has facilitated in data storage and data sharing and communication with public health agencies, which has helped the market to grow during the previous forecasted peri…- 中枢神経系疾患治療薬の世界市場（～2026年） A drug used to treat neurological diseases that affect the functioning of the brain or spinal cord in the central nervous system Market Analysis and Insights: Global Drugs for Central Nervous System Diseases Market The global Drugs for Central Nervous System Diseases market size is projected to reac…
- C型肝炎治療薬の世界市場（～2026年） Hepatitis is inflammation of the liver characterized by yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay colored stools etc. Hepatitis is caused by a variety of factors both microbial and non-microbial. However hepa…
- 感染症治療の世界市場（～2026年） Treatment for Infectious Diseases. Treatment of viral infections such as HIV involves patient care and moral support including antiretroviral therapy. Bacterial infections can be treated by administering antibiotics to the patients. Market Analysis and Insights: Global Infectious Disease Treatment M…
- 免疫療法薬の世界市場（～2026年） Immunotherapy is a type of cancer treatment that helps your immune system fight cancer. The immune system helps your body fight infections and other diseases. It is made up of white blood cells and organs and tissues of the lymph system. North America is expected to account for largest share in the …